What are the available bottle sizes?

The product is available in 500ml, 1000ml, 250ml, and 100ml soft plastic bottles.

Is the manufacturer certified?

Yes, the company has GMP approval by the SFDA of China.

Ringer Lactate Injection Medicine Infusion 500ml

Name: Ringer Lactate Injection Medicine Infusion 500ml
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2037802942

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.17-0.20

10,000 Pieces

Sample price:US$0.20/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

30 Bottles/Carton

Specification

500ml plastic bottle

Origin

China

HS Code

30049090

Production Capacity

1000000pieces/Year

Key features

Comprehensive Electrolyte Balance: Corrects metabolic acid toxicosis and dehydration by adjusting electrolyte and acid-alkali equilibrium.

Suitable for All Age Groups: Indicated for use in elderly, children, and adults requiring intravenous infusion therapy.

GMP Certified Manufacturing: Produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd. with SFDA GMP approval.

High Volume Production Capacity: Annual output exceeds 1200 million bottles, including 40 million soft plastic bottles.

Global Market Reach: Products exported to South America, Africa, Asia, Oceania, and the Middle East.

Clear Liquid Formulation: Colorless, clear liquid containing sodium lactate, sodium chloride, potassium chloride, and calcium chloride.

Established Manufacturer: Company established in 1948 with over 3000 employees and USD 58 million capital.

Multiple Dosage Options: Available in 500ml, 250ml, and 100ml soft plastic bottle specifications.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.